Richard A. Furie, MD, Chief of the Division of Rheumatology at Northwell Health, discusses nipocalimab for the treatment of systemic lupus erythematosus (SLE).
SLE is an autoimmune disease characterized by inflammation in the connective tissues, leading to multisystem involvement and potentially significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. Common signs and symptoms include severe fatigue, malaise, fever, loss of appetite, weight loss, joint pain and swelling, butterfly rash, and muscle pain and weakness.
Nipocalimab has been granted US Food and Drug Administration (FDA) Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Nipocalimab is an immunoselective investigational therapy that lowers harmful immunoglobulin G (IgG) while preserving key immune functions. The Fast Track designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas where unmet needs remain.
Following positive results from the phase 1b JASMINE clinical trial (NCT04882878), which illustrated nipocalimab’s ability to reduce SLE disease activity and potential for steroid sparing, patient enrollment for the phase 3 GARDENIA (NCT07438496) clinical trial has been initiated. GARDENIA is a randomized, double-blind, placebo-controlled, multicenter study of nipocalimab in adults with moderate to severe SLE.
To learn more about SLE and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-autoinflammatory-disorders/